Payment overview · 2025
General Payments
$439.74
19 reported records · 12 companies
Healthcare provider profile · identity verified
Randy Byron Cronic, MD
Allopathic & Osteopathic Physicians|Family Medicine · DULUTH, GA · NPI 1063438679
Verified facts
What the public records show
CMS Open Payments records show Randy Byron Cronic, MD received $439.74 in general payments during 2025 across 19 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $77.42 | 17.6% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.80 | 15.9% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $68.83 | 15.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.57 | 8.8% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $34.62 | 7.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.67 | 7.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.96 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.80 | 5.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.16 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.77 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.05 | 3.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.09 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.74 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $110.09 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.80 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $68.83 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $68.83 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $34.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 620 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 165 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 83 |
| Alprazolam | Alprazolam | 300 | 57 |
| Lisinopril | Lisinopril | 288 | 84 |
| Losartan Potassium | Losartan Potassium | 254 | 72 |
| Gabapentin | Gabapentin | 243 | 68 |
| Montelukast Sodium | Montelukast Sodium | 243 | 84 |
| Omeprazole | Omeprazole | 237 | 73 |
| Sertraline Hcl | Sertraline Hcl | 222 | 48 |
| Metformin Hcl | Metformin Hcl | 213 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 45 |
| Lorazepam | Lorazepam | 179 | 50 |
| Furosemide | Furosemide | 171 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 48 |
| Trazodone Hcl | Trazodone Hcl | 159 | 47 |
| Tramadol Hcl | Tramadol Hcl | 145 | 44 |
| Metformin Hcl Er | Metformin Hcl | 144 | 47 |
| Allopurinol | Allopurinol | 143 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 132 | 17 |
| Clonazepam | Clonazepam | 122 | 27 |
| Donepezil Hcl | Donepezil Hcl | 122 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 31 |
| Eliquis | Apixaban | 115 | 30 |
| Potassium Chloride | Potassium Chloride | 115 | 37 |
| Meloxicam | Meloxicam | 111 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 24 |
| Azithromycin | Azithromycin | 104 | 78 |
| Carvedilol | Carvedilol | 101 | 31 |
| Prednisone | Prednisone | 99 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 28 |
| Simvastatin | Simvastatin | 85 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 32 |
| Famotidine | Famotidine | 80 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 23 |
| Pregabalin | Pregabalin | 76 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 28 |
| Glimepiride | Glimepiride | 75 | 24 |
| Synthroid | Levothyroxine Sodium | 72 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 42 |
| Glipizide | Glipizide | 70 | 22 |
| Memantine Hcl | Memantine Hcl | 70 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 21 |
| Mirtazapine | Mirtazapine | 68 | 29 |
| Bupropion Xl | Bupropion Hcl | 62 | 17 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 16 |
| Divalproex Sodium | Divalproex Sodium | 60 | 11 |
| Atenolol | Atenolol | 58 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 11 |
| Fluconazole | Fluconazole | 55 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 15 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 15 |
| Diazepam | Diazepam | 48 | suppressed |
| Baclofen | Baclofen | 47 | 15 |
| Buspirone Hcl | Buspirone Hcl | 47 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 36 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 18 |
| Ondansetron Odt | Ondansetron | 42 | 19 |
| Promethazine Hcl | Promethazine Hcl | 41 | 15 |
| Alendronate Sodium | Alendronate Sodium | 40 | 12 |
| Cephalexin | Cephalexin | 38 | 24 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Finasteride | Finasteride | 37 | 14 |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 12 |
| Valsartan | Valsartan | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 14 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 13 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Ozempic | Semaglutide | 31 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | 12 |
| Cefdinir | Cefdinir | 28 | 20 |
| Testosterone | Testosterone | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 17 |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | 14 |
| Lactulose | Lactulose | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.74 · 19 records | Otsuka America Pharmaceutical, Inc. | CAPLYTA, Flexitouch Plus, JARDIANCE, JOURNAVX, LOREEV XR, Nimbl, OTEZLA, REPATHA, REXULTI, TERIPARATIDE, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error